<?xml version='1.0' encoding='utf-8'?>
<document id="27162633"><sentence text="Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women."><entity charOffset="89-103" id="DDI-PubMed.27162633.s1.e0" text="levonorgestrel" /><entity charOffset="108-124" id="DDI-PubMed.27162633.s1.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.27162633.s1.e0" e2="DDI-PubMed.27162633.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27162633.s1.e0" e2="DDI-PubMed.27162633.s1.e1" /></sentence><sentence text="Female patients requiring treatment for pulmonary arterial hypertension (PAH) are advised to avoid pregnancy because of the high associated mortality rate" /><sentence text=" Oral contraception is one of the main methods of preventing pregnancy in this context, mandating pharmacokinetic and safety studies for new agents in this setting" /><sentence text=" Riociguat is a soluble guanylate cyclase stimulator approved for treatment of PAH and inoperable and persistent or recurrent chronic thromboembolic pulmonary hypertension" /><sentence text=" This single-center, randomized, nonblinded study involving healthy postmenopausal women investigated the effect of riociguat on plasma concentrations of levonorgestrel (0"><entity charOffset="154-168" id="DDI-PubMed.27162633.s5.e0" text="levonorgestrel" /></sentence><sentence text="15 mg) and ethinylestradiol (0"><entity charOffset="11-27" id="DDI-PubMed.27162633.s6.e0" text="ethinylestradiol" /></sentence><sentence text="03 mg) in a combined oral contraceptive" /><sentence text=" Treatment A was a single oral tablet of levonorgestrel-ethinylestradiol"><entity charOffset="41-55" id="DDI-PubMed.27162633.s8.e0" text="levonorgestrel" /><entity charOffset="56-72" id="DDI-PubMed.27162633.s8.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.27162633.s8.e0" e2="DDI-PubMed.27162633.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27162633.s8.e0" e2="DDI-PubMed.27162633.s8.e1" /></sentence><sentence text=" In treatment B, subjects received 2" /><sentence text="5 mg riociguat 3 times daily for 12 days" /><sentence text=" On the eighth day, they also received a single oral tablet of levonorgestrel-ethinylestradiol"><entity charOffset="63-77" id="DDI-PubMed.27162633.s11.e0" text="levonorgestrel" /><entity charOffset="78-94" id="DDI-PubMed.27162633.s11.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.27162633.s11.e0" e2="DDI-PubMed.27162633.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27162633.s11.e0" e2="DDI-PubMed.27162633.s11.e1" /></sentence><sentence text=" Subjects received both regimens in a crossover design" /><sentence text=" There was no change in area under the plasma concentration-time curves of levonorgestrel or ethinylestradiol or maximum concentration in plasma (C max) of levonorgestrel during combined administration versus levonorgestrel-ethinylestradiol alone"><entity charOffset="75-89" id="DDI-PubMed.27162633.s13.e0" text="levonorgestrel" /><entity charOffset="93-109" id="DDI-PubMed.27162633.s13.e1" text="ethinylestradiol" /><entity charOffset="156-170" id="DDI-PubMed.27162633.s13.e2" text="levonorgestrel" /><entity charOffset="209-223" id="DDI-PubMed.27162633.s13.e3" text="levonorgestrel" /><entity charOffset="224-240" id="DDI-PubMed.27162633.s13.e4" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e0" e2="DDI-PubMed.27162633.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e0" e2="DDI-PubMed.27162633.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e0" e2="DDI-PubMed.27162633.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e0" e2="DDI-PubMed.27162633.s13.e3" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e0" e2="DDI-PubMed.27162633.s13.e4" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e1" e2="DDI-PubMed.27162633.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e1" e2="DDI-PubMed.27162633.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e1" e2="DDI-PubMed.27162633.s13.e3" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e1" e2="DDI-PubMed.27162633.s13.e4" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e2" e2="DDI-PubMed.27162633.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e2" e2="DDI-PubMed.27162633.s13.e3" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e2" e2="DDI-PubMed.27162633.s13.e4" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e3" e2="DDI-PubMed.27162633.s13.e3" /><pair ddi="false" e1="DDI-PubMed.27162633.s13.e3" e2="DDI-PubMed.27162633.s13.e4" /></sentence><sentence text=" A 20% increase in the C max of ethinylestradiol was noted during coadministration; this is not anticipated to adversely impact the contraceptive efficacy or to require any dose adjustment for ethinylestradiol"><entity charOffset="32-48" id="DDI-PubMed.27162633.s14.e0" text="ethinylestradiol" /><entity charOffset="193-209" id="DDI-PubMed.27162633.s14.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.27162633.s14.e0" e2="DDI-PubMed.27162633.s14.e0" /><pair ddi="true" e1="DDI-PubMed.27162633.s14.e0" e2="DDI-PubMed.27162633.s14.e1" /></sentence><sentence text=" Plasma concentrations and exposures of riociguat were within the expected range and were not influenced by coadministration with levonorgestrel-ethinylestradiol"><entity charOffset="130-144" id="DDI-PubMed.27162633.s15.e0" text="levonorgestrel" /><entity charOffset="145-161" id="DDI-PubMed.27162633.s15.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.27162633.s15.e0" e2="DDI-PubMed.27162633.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27162633.s15.e0" e2="DDI-PubMed.27162633.s15.e1" /></sentence><sentence text=" Combined treatment was safe and well tolerated" /><sentence text=" In conclusion, riociguat did not change the exposure to levonorgestrel or ethinylestradiol relative to oral contraceptive administered alone"><entity charOffset="57-71" id="DDI-PubMed.27162633.s17.e0" text="levonorgestrel" /><entity charOffset="75-91" id="DDI-PubMed.27162633.s17.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.27162633.s17.e0" e2="DDI-PubMed.27162633.s17.e0" /><pair ddi="false" e1="DDI-PubMed.27162633.s17.e0" e2="DDI-PubMed.27162633.s17.e1" /></sentence><sentence text=" " /></document>